Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 175-179

  Hu, Shiqi ^a   Lee, Eunhye ^b   Wang, Chi ^c   Wang, Jinqiang ^a   Zhou, Zhuxian ^a   Li, Yixian ^b   Li, Xiaoyi ^c   Tang, Jianbin ^a   Lee, Don Haeng ^b   Liu, Xiangrui ^a   Shen, Youqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Utah Inha DDS and Advanced Theapeutics Research Center   (South Korea)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

7 Ethyl 10 hydroxycamptothecin (SN38); Excipient free; Nanodispersion; Nanomedicine; Water insoluble drugs

Indexed keywords

BIOCHEMISTRY; BLOCK COPOLYMERS; BODY FLUIDS; CHEMOTHERAPY; DISEASES; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; SURFACE ACTIVE AGENTS;

7-ETHYL-10-HYDROXYCAMPTOTHECIN (SN38); AMPHIPHILIC BLOCK COPOLYMERS; ANTICANCER ACTIVITIES; CAMPTOTHECIN (CPT); CANCER CHEMOTHERAPY; EXCIPIENT-FREE; INSOLUBLE DRUG; NANO-DISPERSIONS;

HYDROPHOBICITY;

AMPHOPHILE; CAMPTOTHECIN; EXCIPIENT; FIRTECAN; IRINOTECAN; NANOPARTICLE; PACLITAXEL; SURFACTANT; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SOLUBILITY; DRUG TRANSPORT; EROSION; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY; ULCER; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; INSTITUTE FOR CANCER RESEARCH MOUSE; MEDICINAL CHEMISTRY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; MICE, INBRED ICR; NANOPARTICLES; SURFACE-ACTIVE AGENTS;

EID: 84945246852     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.031     Document Type: Article

References (26)

1. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications Int. J. Pharm. 420 2011 1 10
2. S.E. Lipshultz, T.R. Cochran, V.I. Franco, and T.L. Miller Treatment-related cardiotoxicity in survivors of childhood cancer Nat. Rev. Clin. Oncol. 10 2013 697 710
3. V. Sahni, D. Choudhury, and Z. Ahmed Chemotherapy-associated renal dysfunction Nat. Rev. Nephrol. 5 2009 450 462
4. D. Schiff, P.Y. Wen, and M.J. van den Bent Neurological adverse effects caused by cytotoxic and targeted therapies Nat. Rev. Clin. Oncol. 6 2009 596 603
5. J.H. Hu, K.P. Johnston, and R.O. Williams Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs Drug. Dev. Ind. Pharm. 30 2004 233 245
6. L.H. Reddy, and D. Bazile Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics Adv. Drug Deliv. Rev. 71 2014 34 57
7. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
8. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
9. H. Yoshizawa, S. Nishino, K. Shiomori, S. Natsugoe, T. Aiko, and Y. Kitamura Surface morphology control of polylactide microspheres enclosing irinotecan hydrochloride Int. J. Pharm. 296 2005 112 116
10. J.A. Zhang, T. Xuan, M. Parmar, L. Ma, S. Ugwu, S. Ali, and I. Ahmad Development and characterization of a novel liposome-based formulation of SN-38 Int. J. Pharm. 270 2004 93 107
11. P. Ebrahimnejad, R. Dinarvand, A. Sajadi, M.R. Jaafari, A.R. Nomani, E. Azizi, M. Rad-Malekshahi, and F. Atyabi Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines Nanomedicine 6 2010 478 485
12. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, and I.D. Horak Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model Clin. Cancer Res. 14 2008 1888 1896
13. J.F. Marier, L. Pheng, M.M. Trinh, H.A. Burris, S. Jones, K. Anderson, S. Warner, and D. Porubek Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors J. Pharm. Sci. 100 2011 4536 4545
14. F. Meyer-Losic, C. Nicolazzi, J. Quinonero, F. Ribes, M. Michel, V. Dubois, C. de Coupade, M. Boukaissi, A.S. Chene, I. Tranchant, V. Arranz, I. Zoubaa, J.S. Fruchart, D. Ravel, and J. Kearsey DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies Clin. Cancer Res. 14 2008 2145 2153
15. E. Dotan, J. Berlin, A. Starodub, M.J. Guarino, S.J. Cohen, P.P. Maliakal, S.V. Govindan, W.A. Wegener, R.M. Sharkey, and D.M. Goldenberg Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: phase I study J. Clin. Oncol. 32 2014
16. V. Bala, S.S. Rao, B.J. Boyd, and C.A. Prestidge Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38 J. Control. Release 172 2013 48 61
17. C.R. Garrett, T.S. Bekaii-Saab, T. Ryan, G.A. Fisher, S. Clive, P. Kavan, E. Shacham-Shmueli, A. Buchbinder, and R.M. Goldberg Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer Cancer 119 2013 4223 4230
18. V.J. Venditto, and F.C. Szoka Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65 2013 80 88
19. Q.H. Sun, M. Radosz, and Y.Q. Shen Challenges in design of translational nanocarriers J. Control. Release 164 2012 156 169
20. Y.Q. Shen, E.L. Jin, B. Zhang, C.J. Murphy, M.H. Sui, J. Zhao, J.Q. Wang, J.B. Tang, M.H. Fan, E. Van Kirk, and W.J. Murdoch Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery J. Am. Chem. Soc. 132 2010 4259 4265
21. D. Douroumis, and A. Fahr Drug Delivery Strategies for Poorly Water-soluble Drugs 2012 John Wiley & Sons Chichester, West Sussex
22. A. Stein, W. Voigt, and K. Jordan Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management Ther. Adv. Med. Oncol. 2 2010 51 63
23. L.B. Saltz Understanding and managing chemotherapy-induced diarrhea J. Support. Oncol. 1 2003 35 46
24. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat. Rev. Cancer 6 2006 789 802
25. I. Nabiev, F. Fleury, I. Kudelina, Y. Pommier, F. Charton, J.F. Riou, A.J. Alix, and M. Manfait Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action Biochem. Pharmacol. 55 1998 1163 1174
26. J.G. Slatter, L.J. Schaaf, J.P. Sams, K.L. Feenstra, M.G. Johnson, P.A. Bombardt, K.S. Cathcart, M.T. Verburg, L.K. Pearson, L.D. Compton, L.L. Miller, D.S. Baker, C.V. Pesheck, and R.S. Lord Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [C-14] CPT-11 in cancer patients Drug Metab. Dispos. 28 2000 423 433